XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative Arrangements - Narrative (Details)
course in Millions, $ in Millions
 1 Months Ended 3 Months Ended
Jan. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2022
USD ($)
market
course
Mar. 31, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Amortization     $ 699 $ 514
Number of markets (more than) | market     30  
Remaining minimum courses committed (in courses) | course     3.4  
Sales     $ 15,901 10,627
Operating Segments        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales     15,589 10,656
Operating Segments | Pharmaceutical        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales     14,107 9,238
Lynparza        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Amortization     250  
Lynparza | Other Noncurrent Assets        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Finite-lived intangible assets     1,600  
Lenvima | Operating Segments | Pharmaceutical        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales     227 130
Lenvima | Other Noncurrent Assets        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Finite-lived intangible assets     973  
Verquvo | Other Intangible Assets        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Finite-lived intangible assets     65  
Adempas | Operating Segments | Pharmaceutical        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales     61 55
Adempas | Other Intangible Assets        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Finite-lived intangible assets     758  
Alliance Revenue - Reblozyl | Operating Segments | Pharmaceutical        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales     52 $ 0
AstraZeneca | Sales-Based Milestones | Lynparza        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Probable contingent payments     600  
Liabilities     600  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lynparza        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales-based milestone payments     400  
Potential future sales-based milestone payments     2,100  
Milestone payment accrued     175  
Potential future regulatory milestone payments     1,300  
Eisai        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License option payment related to collaborative arrangement   $ 125    
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lenvima        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales-based milestone payments     300  
Potential future sales-based milestone payments     2,600  
Milestone payment accrued     25  
Milestone payments accrued but not yet paid     300  
Capitalized milestone payment     $ 25  
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales-based milestone payments $ 400      
Bristol Myers Squibb | Licensing Agreements        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Royalty rate, deduction     0.50  
Royalties     $ 32  
Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Contingent milestone payments collaborative arrangement     80  
Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Contingent milestone payments collaborative arrangement     $ 20  
Bristol Myers Squibb | Licensing Agreements | Minimum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Royalty rate     20.00%  
Bristol Myers Squibb | Licensing Agreements | Maximum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Royalty rate     24.00%